JP5709758B2 - 体液から細胞を分離するシステム及び方法 - Google Patents
体液から細胞を分離するシステム及び方法 Download PDFInfo
- Publication number
- JP5709758B2 JP5709758B2 JP2011538586A JP2011538586A JP5709758B2 JP 5709758 B2 JP5709758 B2 JP 5709758B2 JP 2011538586 A JP2011538586 A JP 2011538586A JP 2011538586 A JP2011538586 A JP 2011538586A JP 5709758 B2 JP5709758 B2 JP 5709758B2
- Authority
- JP
- Japan
- Prior art keywords
- container
- component materials
- red blood
- blood cells
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 56
- 210000001124 body fluid Anatomy 0.000 title 1
- 239000010839 body fluid Substances 0.000 title 1
- 239000000463 material Substances 0.000 claims description 84
- 210000004027 cell Anatomy 0.000 claims description 47
- 210000003743 erythrocyte Anatomy 0.000 claims description 47
- 239000012465 retentate Substances 0.000 claims description 43
- 238000001914 filtration Methods 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 26
- 238000000605 extraction Methods 0.000 claims description 23
- 238000012545 processing Methods 0.000 claims description 20
- 238000004062 sedimentation Methods 0.000 claims description 18
- 239000012620 biological material Substances 0.000 claims description 17
- 230000002776 aggregation Effects 0.000 claims description 14
- 238000004220 aggregation Methods 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000004891 communication Methods 0.000 claims description 9
- 210000004700 fetal blood Anatomy 0.000 claims description 8
- 210000001185 bone marrow Anatomy 0.000 claims description 7
- 230000003134 recirculating effect Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims 1
- 239000000306 component Substances 0.000 description 43
- 239000000523 sample Substances 0.000 description 43
- 239000002699 waste material Substances 0.000 description 28
- 239000000706 filtrate Substances 0.000 description 27
- 229920002307 Dextran Polymers 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 21
- 231100000252 nontoxic Toxicity 0.000 description 21
- 230000003000 nontoxic effect Effects 0.000 description 21
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 21
- 239000001509 sodium citrate Substances 0.000 description 21
- 229940074404 sodium succinate Drugs 0.000 description 17
- 210000000265 leukocyte Anatomy 0.000 description 16
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 16
- 230000004931 aggregating effect Effects 0.000 description 15
- 238000011084 recovery Methods 0.000 description 14
- 210000000601 blood cell Anatomy 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- 230000001376 precipitating effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 3
- 230000004523 agglutinating effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000008394 flocculating agent Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 229940027278 hetastarch Drugs 0.000 description 3
- 230000005055 memory storage Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229920002123 Pentastarch Polymers 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- HCDITHVDEPPNIL-UHFFFAOYSA-L dipotassium;propanedioate Chemical compound [K+].[K+].[O-]C(=O)CC([O-])=O HCDITHVDEPPNIL-UHFFFAOYSA-L 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940101738 pentastarch Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 231100000169 potential cardiovascular toxicity Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3403—Regulation parameters
- A61M1/341—Regulation parameters by measuring the filtrate rate or volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3403—Regulation parameters
- A61M1/3406—Physical characteristics of the filtrate, e.g. urea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3431—Substitution fluid path upstream of the filter
- A61M1/3434—Substitution fluid path upstream of the filter with pre-dilution and post-dilution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3437—Substitution fluid path downstream of the filter, e.g. post-dilution with filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D36/00—Filter circuits or combinations of filters with other separating devices
- B01D36/04—Combinations of filters with settling tanks
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0605—Metering of fluids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0631—Purification arrangements, e.g. solid phase extraction [SPE]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Clinical Laboratory Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Cardiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/325,672 | 2008-12-01 | ||
| US12/325,672 US8961787B2 (en) | 2008-12-01 | 2008-12-01 | Systems and methods for processing complex biological materials |
| US12/333,926 | 2008-12-12 | ||
| US12/333,926 US20100151438A1 (en) | 2008-12-12 | 2008-12-12 | Methods and kits for enhancing sedimentation and recovery of cells in a sample |
| PCT/SE2009/051327 WO2010064973A1 (en) | 2008-12-01 | 2009-11-24 | System and method for separating cells from body fluids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012510271A JP2012510271A (ja) | 2012-05-10 |
| JP2012510271A5 JP2012510271A5 (enExample) | 2012-06-21 |
| JP5709758B2 true JP5709758B2 (ja) | 2015-04-30 |
Family
ID=42233461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011538586A Expired - Fee Related JP5709758B2 (ja) | 2008-12-01 | 2009-11-24 | 体液から細胞を分離するシステム及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2352533B1 (enExample) |
| JP (1) | JP5709758B2 (enExample) |
| KR (1) | KR101720808B1 (enExample) |
| CN (1) | CN102264410B (enExample) |
| CA (1) | CA2745214C (enExample) |
| WO (1) | WO2010064973A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150299657A1 (en) * | 2014-04-16 | 2015-10-22 | General Electric Company | Gamma stabilized dextran solutions and methods of use |
| US20130131546A1 (en) * | 2011-11-23 | 2013-05-23 | Harvest Technologies Corporation | System for collecting and processing bone marrow |
| GB201306810D0 (en) | 2013-04-15 | 2013-05-29 | Cells4Life Group Llp | Methods of cell separation |
| GB2525202A (en) * | 2014-04-15 | 2015-10-21 | Cells4Life Group Llp | Methods of cell separation |
| AU2016205090A1 (en) * | 2015-01-09 | 2017-07-27 | Aviva Biosciences Corporation | Methods and devices for breaking cell aggregation and separating or enriching cells |
| US10859563B2 (en) * | 2015-12-01 | 2020-12-08 | General Electric Company | Erythrocyte aggregation and leukocyte isolation |
| CN106267418B (zh) * | 2016-07-01 | 2019-01-22 | 翁炳焕 | 母胎血型不合抗体吸附治疗仪 |
| EP3470142A1 (de) | 2017-10-11 | 2019-04-17 | Orthogen AG | Vorrichtung mit einer ersten kammer zur aufnahme eines körperfluids |
| BR112021011482A2 (pt) * | 2018-12-13 | 2021-08-31 | Koligo Therapeutics, Inc. | Aparelho de separação de células e métodos de uso |
| JP7580076B2 (ja) * | 2019-01-24 | 2024-11-11 | 住友ゴム工業株式会社 | 細胞培養装置及び細胞培養方法 |
| US20220169968A1 (en) * | 2019-03-26 | 2022-06-02 | Kyoto Seisakusho Co., Ltd. | Cell suspension treatment apparatus |
| JP7390677B2 (ja) * | 2019-03-26 | 2023-12-04 | キヤノン株式会社 | 細胞懸濁液処理装置 |
| CN109893902A (zh) * | 2019-04-11 | 2019-06-18 | 四川汇宇生物技术有限公司 | 一种明胶分离提纯系统 |
| EP4377470A4 (en) * | 2021-07-30 | 2025-09-10 | Ge Prec Healthcare Llc | TECHNIQUES FOR ISOLATION OR ANALYSIS OF BACTERIAL PATHOGENS FROM SAMPLES TAKEN FROM PATIENTS |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663058A (en) * | 1983-10-11 | 1987-05-05 | E. I. Du Pont De Nemours And Company | Process for continuous separation of leukocyte/platelet-enriched fraction from whole blood |
| AT405018B (de) * | 1992-06-10 | 1999-04-26 | Pall Corp | Verfahren zur behandlung eines biologischen fluids |
| WO1994003217A1 (en) * | 1992-07-31 | 1994-02-17 | Wainwright Basil E | Apparatus and method for inactivation of human immunodeficiency virus |
| US5397479A (en) * | 1993-04-26 | 1995-03-14 | International Remote Imaging Systems, Inc. | Composition and method for enrichment of white blood cells from whole human blood |
| PT815138E (pt) * | 1995-03-23 | 2002-12-31 | Biopure Corp | Substituto sanguineo de hemoglobina polimerizada estavel |
| US6444471B1 (en) * | 1999-10-18 | 2002-09-03 | Research & Diagnostic Systems, Inc. | Reticulocyte containing complete blood control |
| EP1439897B1 (en) * | 2001-10-11 | 2010-09-01 | Aviva Biosciences Corporation | Methods for separating rare cells from fluid samples |
| US9144583B2 (en) * | 2002-03-29 | 2015-09-29 | Tissue Genesis, Inc. | Cell separation apparatus and methods of use |
| EP3173141B1 (en) * | 2002-06-19 | 2019-09-04 | NorthWest Biotherapeutics, Inc. | Tangential flow filtration device and methods for leukocyte enrichment |
| DE102004018347A1 (de) * | 2004-04-06 | 2005-10-27 | Manfred Dr. Schmolz | Wundheilungsfördende Botenstoffmischung |
| JP4925159B2 (ja) * | 2005-10-12 | 2012-04-25 | 日機装株式会社 | 血液浄化装置 |
| WO2007049286A1 (en) * | 2005-10-27 | 2007-05-03 | Tata Memorial Centre | A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma |
| US20100260815A1 (en) * | 2007-06-22 | 2010-10-14 | Circle Biologics , LLC | Fluid concentrator, autologous concentrated body fluids, and uses thereof |
-
2009
- 2009-11-24 CA CA2745214A patent/CA2745214C/en active Active
- 2009-11-24 EP EP09830656.6A patent/EP2352533B1/en active Active
- 2009-11-24 CN CN200980149086.1A patent/CN102264410B/zh not_active Expired - Fee Related
- 2009-11-24 KR KR1020117012466A patent/KR101720808B1/ko not_active Expired - Fee Related
- 2009-11-24 WO PCT/SE2009/051327 patent/WO2010064973A1/en not_active Ceased
- 2009-11-24 JP JP2011538586A patent/JP5709758B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102264410A (zh) | 2011-11-30 |
| KR20110090995A (ko) | 2011-08-10 |
| CA2745214C (en) | 2017-11-21 |
| KR101720808B1 (ko) | 2017-03-28 |
| EP2352533B1 (en) | 2018-01-10 |
| CN102264410B (zh) | 2016-08-03 |
| EP2352533A4 (en) | 2013-08-07 |
| CA2745214A1 (en) | 2010-06-10 |
| WO2010064973A1 (en) | 2010-06-10 |
| EP2352533A1 (en) | 2011-08-10 |
| JP2012510271A (ja) | 2012-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5709758B2 (ja) | 体液から細胞を分離するシステム及び方法 | |
| US9709549B2 (en) | Systems and methods for processing complex biological materials | |
| JP4846782B2 (ja) | 再生医療のための、成人幹細胞を含む細胞サブセットを採集、加工及び移植するための統合システム | |
| US9095798B2 (en) | Centrifuge separation method and apparatus using a medium density fluid | |
| CN213222222U (zh) | 从生物样品中选择性提取组分的仪器、系统和试剂盒 | |
| JPH0216455A (ja) | 低密度リポ蛋白質の選択的体外沈澱法 | |
| JP2015506674A (ja) | 試料処理のための方法および装置 | |
| JP2011509657A (ja) | 濾過により生体物質を分離する装置および方法 | |
| WO2012026970A2 (en) | Centrifuge and separation vessel therefore | |
| KR102100665B1 (ko) | 원심분리를 위한 장치 및 그 방법 | |
| US20210262908A1 (en) | Size-based separation method for highly concentrating extracellular vesicle in fluid sample | |
| US20230384191A1 (en) | Sample preparation system and sample preparation method | |
| HK1164189B (en) | System and method for separating cells from body fluids | |
| HK1164189A (en) | System and method for separating cells from body fluids | |
| US12090256B2 (en) | Systems and methods for platelet filtration using an additive | |
| Bozic et al. | Pursuing mechanisms of extracellular vesicle formation. Effects of sample processing | |
| JP2025064735A (ja) | 分離装置及び分離方法 | |
| CN120078012A (zh) | 一种脐带血来源单个核细胞的高活性保存方法及其应用 | |
| CN113557043A (zh) | 细胞洗涤装置 | |
| HK1119094B (en) | Integrated system for collecting, processing and transplanting cell subsets, including adult stem cells, for regenerative medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120329 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130327 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130808 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130820 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140610 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140909 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140917 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141009 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141110 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150303 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5709758 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |